Antitrust Antitrust

Leadiant to challenge Dutch fine over excessive prices for orphan drug CDCA

By Tono Gil and Lewis Crofts
  • 19 Jul 2021 08:48
  • 19 Jul 2021 09:15
Leadiant has said it will challenge a fine of about 19 million euros ($22 million), which the Dutch antitrust watchdog imposed today over excessive prices for its orphan drug CDCA.
The Authority for Consumers and Markets said that Leadiant held a dominant position on CDCA-based drugs for the treatment of the rare

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Tono Gil

Regulatory Reporter


Tono is a competition reporter for MLex in Brussels. Prior to joining MLex, he worked as a trainee in the European Parliament and as a correspondent in Valencia and Buenos Aires for the Spanish news agency EFE. Tono holds a degree in Journalism from the University of Valencia and a master in Transmedia Journalism.

Lewis Crofts

Editor-In-Chief


Lewis leads MLex's editorial strategy, content direction, quality and development. He has a reputation for breaking stories and providing analysis on complex legal disputes before regulators and courts around the globe. He has also developed MLex's unrivalled coverage of competition policy, litigation, regulation, Brexit and international investigations.

Discover MLex

Stay on top of global regulatory developments

Latest News